Despite encouraging preclinical safety and efficacy data
for its RNAi-based hepatitis C treatment, Somagenics has decided to
step back from its previous plan to push the agent into phase I testing
this year as it waits to see how more advanced small-molecule therapies
fare in late-stage clinical trials, a company official said this week.
In the interim, however, the company is not standing still. Somagenics CEO Brian Johnston told Gene Silencing News
this week that the firm is continuing to refine its HCV treatment to
target additional sites on the virus’ genome as it explores other
therapeutic indications and tests the microRNA diagnostic waters.